An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

PSMA PET scans significantly enhance detection and staging of prostate cancer, improving patient stratification and survival outcomes. Three FDA-approved PSMA PET scans are available, aiding in both ...

Positron emission tomography (PET) scans can detect cancer earlier than other imaging tests. But some types of cancer are harder to detect on a PET scan. In particular, they may miss cancers that ...

PET scans can light up tumors in the body and help doctors determine if they are cancerous or benign (noncancerous). The results of a PET scan help guide medical decisions. A PET scan is a type of ...

BALTIMORE (Reuters) - The medical imaging industry called for the Medicare government health plan to broaden its coverage of PET scans to additional cancer types, asking an advisory panel on Wednesday ...

PET scans may serve as both a diagnostic and prognostic tool in giant cell arteritis (GCA), according to a new study. In over 100 patients with GCA who underwent 18 F-fluorodeoxyglucose (FDG) PET ...